Cite Filings / ADAPY / 0000902664-25-000083

Feed Companies Filings Check

Sign in

SCHEDULE 13G/A

Statement of Beneficial Ownership

Adaptimmune Therapeutics PLC Filed 2025-01-08 Acc 0000902664-25-000083

Documents 1

SCHEDULE 13G/A Statement of Beneficial Ownership , xslSCHEDULE_13G_X01/primary_doc.xml

Around this filing

2025-02-11 SCHEDULE 13G/A Statement of Beneficial Ownership
2025-01-15 4 Chief Executive Officer sold 59,569 shares at an average $0.58 ($34,639)
2025-01-15 4 Chief Commercial Officer sold 12,991 shares at $0.57 ($7,467)
2025-01-15 4 Chief Medical Officer sold 22,195 shares at an average $0.58 ($12,920)
2025-01-15 4 Chief Patient Supply Officer sold 19,542 shares at an average $0.58 ($11,360)
2025-01-08 SCHEDULE 13G/A Statement of Beneficial Ownership
2024-12-05 SCHEDULE 13G/A Statement of Beneficial Ownership

Link to a passage

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

External

SEC EDGAR (opens in new tab)

Loading xslSCHEDULE_13G_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…